Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Green Cross Corporation (142280:KRX), powered by AI.
Green Cross Corporation is currently trading at ₩6,230. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Green Cross Corporation on Alpha Lenz.
Green Cross Corporation's P/E ratio is 37.1.
“Green Cross Corporation trades at a P/E of 37.1 (premium valuation) with solid ROE of 8.6%.”
Ask for details →Green Cross Corporation is a globally recognized biopharmaceutical company dedicated to the development, manufacturing, and distribution of various healthcare products. Primarily focusing on vaccines and plasma-derived therapies, Green Cross plays a crucial role in advancing public health standards. The company's innovative approach in biopharma research and development aids in addressing unmet medical needs, particularly in the areas of immunology, hematology, and rare diseases. Green Cross Corporation's impactful presence is observed within the healthcare and pharmaceutical sectors, where it contributes significantly to therapeutic advancements and healthcare solutions. With a robust pipeline of products, the corporation is instrumental in mitigating disease impact through cutting-edge biotechnological applications. Further establishing its significance, Green Cross operates with a commitment to sustainable practices, aligning with global health initiatives and environmental stewardship. Through strategic partnerships and a focus on genetic engineering, Green Cross continues to foster medical advancements and plays a vital role in enhancing global health outcomes.
“Green Cross Corporation trades at a P/E of 37.1 (premium valuation) with solid ROE of 8.6%.”
Ask for details →Green Cross Corporation (ticker: 142280) is a company listed on KRX in the Healthcare sector (Drug Manufacturers - Specialty & Generic). It has approximately 122 employees. Market cap is $135.9B.
The current price is ₩6,230 with a P/E ratio of 37.07x and P/B of 3.06x.
ROE is 8.57% and operating margin is 2.66%. Annual revenue is $108.4B.